In major Indian cities, diagnostic laboratories offer consumers extensive testing packages that can include anywhere from forty to ninety different tests. These packages, often presented as a menu, include indicators such as fasting glucose, thyroid panels, Vitamin D, cardiac markers, and tumor markers, and are sold at prices perceived as a bargain rather than a medical solution.
Furthermore, it is rarely determined whether these tests were prescribed by a doctor, as they are sold directly. This issue is a less visible aspect of the Indian healthcare system compared to the shortage of hospital beds or rural physicians. Another problem has emerged among affluent and upwardly mobile city dwellers: overly frequent and excessive testing for minor reasons.
Corporate wellness programs provide annual full-body checkups as a bonus, and insurance companies include preventive panels in premium plans to attract clients. Diagnostic chains conduct scan sales comparable to promotions in electronics stores. As a result, people who appear healthy and have no symptoms receive reports with dozens of parameters, many marked yellow within the normal range, but without a doctor's explanation.
The consequences of this overtesting are serious. A slightly deviated reading on an unnecessary test can trigger subsequent scans, which in turn may lead to a biopsy, causing weeks of anxiety about something that might never have posed a threat.
Doctors note that patients arrive with thick folders of lab results, having no clinical complaints, and are unsure why they were tested at all, yet are convinced that more tests mean better health.
The question is not whether early detection saves lives—it does—but whether the growing testing industry in India has confused detection with reassurance, and reassurance with health.
When Does a Test Truly Become Necessary?
When a physician practicing evidence-based medicine answers the question of test necessity, the answer rarely starts with the test itself. It begins with a dialogue. Dr. Haripriya Jagadish, an internist at Apollo Spectra Hospital in Chennai, states: 'It is an individual matter. Most practitioners follow evidence-based medicine. The doctor gathers a history, which includes all the patient's symptoms, and based on that, tests are ordered.'
The process of taking a medical history is the most subtle part of clinical practice for the patient and is almost absent in the retail testing model. By analyzing symptoms, disease duration, family history, and patient risk factors, the doctor effectively narrows down the list of possible causes before ordering the first test, so that each analysis serves to confirm or exclude something specific. A preventive package advertised on a billboard completely skips this stage, conducting dozens of tests without first asking what the patient's body is signaling.
According to Dr. Jagadish, the reasons why a test is truly indicated usually fall into several clearly defined categories. She notes: 'General reasons start with infections, chronic diseases, inflammations, and malignant neoplasms. Everything is based on symptoms and science.' For example, unexplained fever may indicate the need for an infection screening. Unexplained fatigue or weight change combined with family history may justify screening for a chronic condition like diabetes or thyroid dysfunction. Persistent localized pain or an abnormal finding during a physical examination may require investigation for inflammation or, in some cases, malignancy. In every case, the test follows the symptom, not the other way around.
This is the clinical logic that preventive testing packages bypass. Instead of starting with the patient's medical history and narrowing the hypothesis, they start with a menu of everything available and work backward, hoping that volume compensates for the lack of a clinical question. For the generation of practitioners focused on evidence-based medicine, Dr. Jagadish, this inversion is the biggest problem; it is not that the testing itself is harmful, but that testing without a preceding clinical reason deprives it of the context necessary for interpreting the results.
Regulation Lags Behind
Unlike pharmaceutical companies in India, which must comply with laws restricting the advertising of prescription drugs, when diagnostic chains advertise a package of forty preventive tests, including some with potential cancer screening capabilities, an equivalent regulatory threshold is absent. This test package exploits a regulatory loophole: it is not a drug and is not a procedure requiring a prescription, and therefore it is largely free to be marketed like any consumer good, using discounts, urgency, and appeals to fear.
Oversight of diagnostic laboratories in India exists, but it focuses almost exclusively on technical quality. Accreditation bodies set standards for test accuracy, but they do not determine whether this test should be sold to an asymptomatic client or how the results should be delivered. There is no requirement for preliminary consultation before the test, no mandate for a qualified specialist to interpret the results before they reach the patient, and no restrictions on marketing screening tests directly to consumers without clinical indications.
This situation is not unique to India; direct-to-consumer testing is expanding globally, and regulators in some markets have begun to react by tightening requirements on the claims of these tests and how aggressively they can be advertised to healthy individuals. India's distinguishing feature is the speed of this catch-up. As the retail diagnostics market rapidly scales up in megacities and now in smaller towns, the regulatory system controlling the sale and recipients of these tests has largely remained unchanged, designed for an era when a blood test required a doctor's request.
The Economy of Anxiety
The report itself rarely comes with context. It arrives as a PDF file or a printed sheet containing rows of values, comparison ranges in parentheses, and several marked in red or yellow, without explaining what these deviations mean for the specific person's health. For a patient who has no symptoms and no clinical history prompting the test, this ambiguity becomes fertile ground for anxiety.
This scenario is familiar to clinicians. A slightly elevated tumor marker, a borderline nodule on a random scan, a value just outside the 'normal' range in a test that was not initially clinically justified—these findings, once flagged, tend to launch a cascade. The patient consults a specialist. The specialist, unable to dismiss the concern based on a single indicator, orders a repeat scan or retest. In some cases, this can escalate to a biopsy or invasive procedure to examine a finding that may have had no initial clinical significance.
Dr. Jagadish points to this as one of the central risks of unlimited testing. She states: 'The problem with performing too many tests, especially cancer screenings, is that if you do them and get an abnormal value without medical correlation, it can do more harm than good.' She adds: 'This generation, in particular, experiences a lot of anxiety about this. It unnecessarily increases the patient's medical expenses as well as psychological trauma.'
This psychological damage is rarely discussed in conversations about overtesting, which more often focus on financial losses or clinical inefficiency. But for the patient sitting with an unexplained abnormal result, the experience is rarely purely administrative. It is weeks of uncertainty, repeated consultations, and a growing obsession with a number that might resolve itself or never have mattered.
What is lost in this cycle is the fact that not every anomaly requires intervention. Medicine has long understood that some findings are incidental, present but clinically irrelevant, yet the system that first tests and then interprets leaves little room for this nuance. The result is a quiet, largely undocumented cost of overtesting: it is not only the money spent on unnecessary follow-up examinations but also the accumulated burden of worry carried by people who were not actually ill.
